A novel class of conserved transcription factors has been identified from the molecular cloning of AF10, the gene involved in the t(10;11)(p12;q23) translocation of acute myeloid leukemias. AFlO encodes a 109-kD protein of 1,027 amino acids and contains an N-terminal zinc finger region and a C-terminal leucine zipper. These structures have been found to be conserved in sequence and position in three T HAS BECOME APPARENT that many genes deregulated in chromosome translocations have features characteristic of known transcription factors.'.' The resultant expression of abnormal proteins containing features such as zinc fingers, leucine zippers, AT hooks, and homeodomains appears to be critical in the development of leukemia and other cancers. An unusual feature of translocations affecting chromosome 1 lq23 is that at least 15 different partner chromosome regions can be involved3 and they can occur in adult and pediatric leukemias with a range of morphologic classifications. At the molecular level, most of the breakpoints on 1 lq23 have been shown to occur within a 9-kb region of genomic DNA. This region includes exons 5 to 10 of the gene known variously as ALL-l, Htrx-l, HRX, or MLL, the sequence of which encodes a 431-kD protein with significant regions of homology to the Drosophila trithorax p r~t e i n .~" Structural features noted within this gene have included elements that have homologies to known motifs, including AT hooks, zinc fingers, DNA methyl transferase-like regions, and small nuclear ribonucleoprotein. The HRX protein could thus be a transcriptional regulator.
T HAS BECOME APPARENT that many genes deregulated in chromosome translocations have features characteristic of known transcription factors.'.' The resultant expression of abnormal proteins containing features such as zinc fingers, leucine zippers, AT hooks, and homeodomains appears to be critical in the development of leukemia and other cancers. An unusual feature of translocations affecting chromosome 1 lq23 is that at least 15 different partner chromosome regions can be involved3 and they can occur in adult and pediatric leukemias with a range of morphologic classifications. At the molecular level, most of the breakpoints on 1 lq23 have been shown to occur within a 9-kb region of genomic DNA. This region includes exons 5 to 10 of the gene known variously as ALL-l, Htrx-l, HRX, or MLL, the sequence of which encodes a 431-kD protein with significant regions of homology to the Drosophila trithorax p r~t e i n .~" Structural features noted within this gene have included elements that have homologies to known motifs, including AT hooks, zinc fingers, DNA methyl transferase-like regions, and small nuclear ribonucleoprotein. The HRX protein could thus be a transcriptional regulator.
A number of the translocations involving 1 lq23 have been shown to result in the expression of fusion mRNAs with HRX sequence fused in-frame to sequence from the partner chromosome.6."'' A further form of deregulation of HRX has recently been found in which a partial in-frame duplication of the region N-terminal to the zinc fingers had occurred in leukemias without apparent chromosomal translocations.I3
Although AF-9 and ENL share substantial sequence homology, the other partner genes appear to be unrelated to each other. In this report, we identified the partner gene (AF10) involved in the t( 10; 1 l)(p12;q23) translocation and show that it appears to be a member of a unique family of proteins related through conserved zinc finger and leucine zipper motifs.
tient C is a 43-year-old woman diagnosed as having AML-MS with the karyotype 51, XX, +3, +8, +der(lO)t(10;1l)(p12;q23),
Nucleic acids analysis.
DNA and RNA were extracted using standard protocols. After completed digestion with appropriate restriction endonuclease, genomic DNA (10 pg) was electrophoresed in a 0.7% agarose gel, denatured, and transferred onto nylon membranes (Hybond-N; Amersham, Les Ulis, France). Aliquots of 20 pg of total RNA or 1 pg of polyadenylated RNA were electrophoresed in 1% agarose gel containing formaldehyde and blotted onto the same membranes. Filters were hybridized overnight with randomly primed "P-labeled probes. Hybridization and washing of the blots were performed under stringent conditions, as described previously." The HRX probes have been described previ0us1y.l~
Isolation of the fusion junctions from HRX mRNA. Cryopreserved peripheral blood cells from patient A were thawed and incubated in 10% fetal calf serum medium to neutralize the dimethylsulfoxide (DMSO). Five to 10 million cells were washed in sterile phosphate-buffered saline (PBS) and total RNA was extracted by the RNAzol-B (Biogenesis, Poole, UK) method" and stored frozen in water at -20°C. To clone the fusion junction in the mRNA, a 3'-RACE strategy was adapted.
A 3' RACE kit was used (Life Technologies Inc, Paisley, UK), but first-strand cDNA synthesis was performed using a specially designed "random hexamer" adapter primer (5'-GGCCACGCGTCGACTAGTACNNNNNN-3'). Firstround polymerase chain reaction (PCR) was performed in 50 pL of 10 mmoliL Tris-HCl, pH 9.0, 50 mmolL KCI, 1.5 mmoE MgCI2, 0.2 mmolL each dNTP, and 1 U of Taq polymerase, with a genespecific primer designed from exon 5 of the HRX gene (5"CAC-CTACTACAGGACCGCCAAG-3') and the universal amplification t(lO;ll)(p12;q23), +19, +21.
primer (S'-CUACUACUACUAGGCCACGCGTCGACTAGT-3' ).
Second-round PCR was performed using a nested HRX primer tailed for use of the UDG (Life Technologies Inc) cloning system (5'-CAUCAUCAUCAUAACCACTCCTAGTGAGCCCAAG-3'). The PCR products were cloned using the Cloneamp system (Life Technologies Inc) and subsequently transformed in DH5a cells (Life Technologies Inc). Colonies were PCR screened for size and specificity and sequenced using a T7 sequencing kit (Pharmacia, St Albans, UK). Cloning of HRX-AF10 fusion cDNAs of patient B was as described previously. ' '
Searching for the reciprocal fused transcript. The cDNA synthesis and the ligation of the oligonucleotide were performed using the 5"AmpliFINDER Race kit (SLIC; Clontech Laboratories, CA) following the manufacturer instructions, except that one fifth of the product of single-strand ligation was submitted to PCR amplification in S0 pL with 10 pmol/L of primers (HRX7-2 nested primer and anchor primer), 200 pmol/L of dNTPs, and 1.5 U of AmpliTaq (Cetus Applied Biosystems, Inc [ABI], Cheshire, UK) in the buffer, as recommended by the supplier. After 35 cycles of amplification, 20 pL of amplified products was purified by electrophoresis on a 1% low melting point gel. One twentieth of the purified products was used in a second amplification with a third nested (HRX7-3) primer and anchor primer. The amplification products were cloned and screened using a "P-labeled HRX7-4 oligonucleotide. DNA sequencing was performed with the T7 Sequencing kit (Pharmacia). Primers were derived from exon 7 sequence of HRX and were as follows: GTCCACTCTGATCCTGTG (HRX7-I) for cDNA synthesis, nested primer HRX7-2 (ATCCTGTGGACTCCATCTG) for the first PCR, and primer HRX7-3 (GCGGATCCAGAGTGCTGA-GGATGTTC) for the second PCR. Oligonucleotides HRX7-4 (CAAAGTGCCTGCATTCTC) and HRX6 Tag (CCCAAGTAT-CCCTGTAAAAC) were used for screening and sequencing.
Bispecific PCR amplification was performed starting from either randomly primed cDNA synthesised from leukemic patient mRNA or cDNA obtained with SLIC strategy. We used CTGCATTGGTTC-CATCCTTG (AFIO BS) and HRX7-3 primers located on chromosomes I O and l 1, respectively.
Library screening. A 160-hp probe was PCR amplified from the novel sequence fused to HRX and used to screen a cDNA library prepared from the Jurkat cell line. Fourteen positive cDNA clones were isolated and their ends were sequenced using the T7 sequencing system (Pharmacia). Three of the largest overlapping clones (T19, T10, and T3) were selected and sequenced on both strands using fuorescently labeled dideoxy terminators on a 373A DNA sequencer (ABI). A human cosmid library was screened using the same probe and four potentially positive clones were isolated.
Of these, one clone (C5) was found, by both PCR and Southern analysis, to contain the sequence present in the 160-hp probe.
Northern anajwis. A commercial Northern blot (Human 11; Clontech) was hybridized using a probe derived from the cDNA clone T3 according to the supplier's instructions. The filter was washed with 0.1 X SSC, 0.1% sodium dodecyl sulfate (SDS) at 50°C and exposed for 16 hours to x-ray film using intensifying screens.
Fluorescent in siru hybridization (FISH) . Competitive in situ hybridization" was performed with cosmid DNA labelled by nick translation using biotin-dATP and the BRL Bio-nick kit (GIBCO-BRL Life Technologies, Paisley, UK). Results were analyzed on a Biorad-Lasersharp MRC600 confocal microscope as previously described." that, in both leukemias from patients A and B, the breakpoints on 1 lq23 were located within the HRX gene.'".'5 Previous studies*-" have shown that 1 lq23 translocations typically result in fusion mRNAs; therefore, it was decided to take advantage of the breakpoint clustering between exons 5 and 10 of HRX. For patient A, a modified 3' RACE method was used to clone cDNA molecules starting at each exon of HRX at which a fusion could have occurred. All clones examined contained HRX sequence in which normal exon fusions were present, except that several independent clones were obtained with novel sequence fused to the 3' end of exon 5 in patient A. Cloning of HRX cDNAs starting from patient B RNA was performed essentially as for patient A." Sequence analysis of two HRX cDNAs showed a novel exon substituted for exon 7 in one of them. This clone hybridized to human DNA within rodent cell hybrids containing human chromosome 10 (data not shown). The novel fused sequences obtained from each patient are shown in Fig 1. These novel sequences encoded open reading frames that were not present within HRX and therefore potentially represented new fusion partner genes.
Characterization and mapping of AFlO cDNA clones. A 160-bp probe from the novel sequence found in patient A was used to screen a cDNA library from the cell line Jurkat and 14 positive clones were isolated. The probe isolated from patient B was also used to isolate a cDNA clone from a RPM1 8226 cDNA library. Sequence analysis of these cDNA clones showed that they were derived from the same gene (designated AFIO, following the nomenclature used for partner genes) and contained the novel sequences in Fig 1. The AFlO cDNA probe was used to isolate a cosmid clone ( c 3 containing homologous sequence, with PCR analysis and Southern blotting confirming that it contained AFlO sequence. FISH to normal metaphase cells confirmed that AFlO was located at chromosome lop12 (Fig 2A) . Additional signals were noted consistently on the short arm of another chromosome. Further investigation showed that this signal was localized to the short arm of chromosome 19. In situ hybridization to leukemic metaphases from patient A For personal use only. on October 23, 2017. by guest www.bloodjournal.org From demonstrated that the AFlO signal was translocated to chromosome I I in the t( IO; 1 1 ) translocation (Fig 2B) . No visible signal remained on the der( IO) chromosome, suggesting that either the breakpoint lay at one end of the cosmid or outside the region contained in the cosmid. Previous FISH analysis of leukemia A using an HRX YAC had shown that chromosome I I sequence was fused onto chromosome IO; therefore. it could be concluded that this t( IO; 1 I ) was a balanced reciprocal translocation.
Artcr/ysis of AFlO seywrtce. A compilation of the nucleotide sequence obtained (3,842 bases; Fig 3) showed a large open reading frame capable of encoding 1,027 amino acids. The positions of the fusion points with HRX are indicated. The nucleotide sequence surrounding the first in-frame ATG matches the optimal consensus sequence for protein initiation.Ix In separate clones, an alternatively spliced exon of 48 bases was observed (nucleotides 1.882 through 1,929 inclusive). Because this exon is bounded at each end by a G nucleotide, it is not possible to define uneqt~ivocally its boundaries, although. as a unit number of codons. its absence does not change the reading frame. The 3' untranslated region is A + T rich (65%) and contains four ATTTA motifs that are thought to destabilize mRNA."' Motif analysis using the PROSITE database indicated that AFlO contained a potential zinc finger domain (amino acids 25 to 194) and a potential leucine zipper region (amino acids 766 to 794). The zinc finger region of AFlO was found to very similar to the equivalent region of AF17."' with 93% identity at the amino acid level (Fig 4A) . Also. the AFlO zinc finger region bore significant homology to the zinc finger region of a protein known as BR140 (previously known as peregrin)." Over a region of I SO amino acids there was SO9 identity and 66% similarity between AFlO and BR140 ( Fig  4A) . Additionally, we have identified a related Coc~rlorIt~b~liri.~ degms gene in a region defined by the cosmid CEFS4F." By splicing this region at predicted splice donor-acceptor sites. it was possible to construct a coding sequence that, when translated, had a high homology to AFIO. This finding is illustrated in Fig 4A and it can be seen that the homology (62% identity over 180 amino acids) included the putative zinc fingcr of AFIO. We have subsequently confimled that this gene (provisionully named CEZF) is expressed as mRNA because partial sequencc exists in ;I C c/e,qms cDNA database (Yuji Kohara. personal communication. 1994).
The leucine zipper sequence of AFlO along with its immediate upstream region was found to be homologous the equivalent sequence in AF17 (Fig 4B) . Significantly. a region of the C e/e,qar~s cosmid CEFS4F was found thnt. when translated. bore similarity to the leucine zipper region of AFIO. This region, previously identified" a s a potential coding sequence (FS4F2.2). had 4 2 9 identity with the leucine zipper and its immediate upstreanl region of AFIO. Although BR 140 contains a region with similarity to the leucine zipper of c-rnyc. this region has less similarity to AFlO and AF17 (Fig 4B) . Outside the conserved zinc fingcr and leucine zipper motifs. AFIO. AF17. BR140. and CEZF bore little resemblance to each other. E.rprc~ssio11 of A FIO nr1d AFlO,/ifsior~ prorlrlcts. Northern analysis performed with an AFlO cDNA prohc showed expression of a single mRNA species of 5.5 kb in a variety of human tissues (Fig S) . Particularly high expression was noted in testis.
A third AML patient (patient C) with the t( IO; I 1 ) translocation was investigated by RT-PCR. An abnormal HRX/ AFlO PCR product was found (data not shown) and sequenced. This consisted of the HRX/AFIO fusion shown in Fig 1: the fusion point is indicated in Fig 3. An extensive investigation using oligonucleotide sense primers to AFlO and antisense primers to exons 6 to 12 of HRX failed to show expression of the rcciprocal AFIO/HRX mRNA in cells from patient A. B. or C. Even after a second, nested PCR. no amplified product could be detected after Southern blotting, under the same conditions in which the expression of HRX, AFIO, and HRXIAFIO could be shown. To ft~rther investigate this question. an SLlC strategy was performed with RNA from patient B. To detect the reciprocal For fused HRX transcript, we used HRX-specific primers located within the exon 7 region in SLIC experiments. cDNA amplification products were subcloned and 192 clones screened with 32P-labeled HRX 7-4 primer to isolated recombinant clones carrying HRX exon 7. An HRX exon 6-specific primer (exon6-Tag) was also used to discriminate between germline HRX cDNA (containing exon 6) and putative AFlO HRX fused cDNA (that should contain exon 7 but not exon 6) clones. Twenty clones hybridizing with HRX 7-4 but not with HRX 6Tag were sequenced. Most of them contained the HRX exon 5 fused directly to HRX exon 7; the remaining clones contained genomic sequences of intron 6. It was thus concluded that the reciprocal AFlO/HRX junction was not expressed.
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DISCUSSION
Several lines of evidence suggest that AF10, AF17, BR140, and CEZF constitute a new family of putative transcription factors. In all four proteins the sequence of the zinc finger motifs and the spacing of the cysteine pairs are highly conserved, with those of AFlO and AF17 being almost identical. Three of the four proteins (AF10, AF17, and CEZF) have clear leucine zipper dimerization motifs C-terminal to the zinc fingers and lack an adjacent basic region required for interaction with DNA.23,24 They also contain a conserved amino acid motif (EQLLE) of unknown function (Fig 4B) . The positions and sequences of these elements are unlike other zinc fingers or leucine zipper motifs found in known transcription factors and indicates that they could be regarded as a new group with a specific functional role. BR140 appears to be the most diverged of this group, having instead a region of homology to the leucine zipper of c-myc and an adjacent basic region. Although these proteins are clearly related through these motifs, they have diverged significantly outside these regions. BR140 was isolated through its copurification with an integrin, but subsequent experiments have failed to confirm this association. Rather, there is good evidence that BR140 is associated with the nucleus,*' although its function is unknown. BR140 can also be distinguished from the others by the presence of a region with similarity to the bromodomain, a region suggested to be involved in protein-protein interactions." The expression of AFlO and BR140 has been shown to be sig- niticantly elevated in testis. The tissue-specific expression patterns of AF17 and CEZF remain to be investigated. Finally, AFlO and AF17 are involved in chromosomal translocations with HRX.
It may be significant that all the t( IO; I I ) and t( 1 1 ; 17) leukemias studied so far ( S patients) involve breakpoints between the zinc fingers and the leucine zippers of AFlO and AF17, respectively. Hence, the chimeric HRX/AFIO and HRX/AF17 proteins have had the zinc fingers of normal HRX replaced with a leucine zipper region. It can be speculated that the substitution of this dimerization motif may give rise to abnormal heterodimers, eg, between AFlO and HRX/AFIO. In this way, the expression of genes normally regulated by AFlO could be disrupted.
AFIO has a relatively high serine (15.6%) and proline (6.6%) content. in common with the other partner proteins AF4. AF9, and ENL that also have nuclear localization signals. Domains rich in serines and prolines have been shown to act as transcriptional activators.'h The other known partner genes, eps-l and AF6, have overall values closer to the normal average of 7% serine and 4% proline and lack nuclear localization signals.
There has been a series of reports of the t( IO; 1 I ) translocation in acute leukemia. The translocation t( IO; 1 I ) and the insertion ins( IO; I I ) have been investigated previously using a YAC" and a cDNA probez7 for the HRX gene. These studies concluded that the breakpoint on chromosome 1 I lay within the HRX gene. The cytogenetic evidence suggests that there may be heterogeneity in the breakpoints on lop. with lOpl IOp12," lOp13,'" IOp14,"' and 1 0~1 5~' all being implicated in rearrangements with I lq23. In addition, a complex insertion ins( IO; 1 I ) has been noted involving and 1 0~1 3 '~ in acute leukemias. Despite the apparent heterogeneity in breakpoints on IOp, it is notable that these events appear to be restricted to acute myelomonocytic leukemia (AML-M4) or acute monoblastic leukemia (AML-MS). The three leukemias examined in this study belonged to this subgroup. Having identified the gene for a recurrent breakpoint on IOp, it will now be possible to investigate whether this variation in breakpoint position is a real difference or is due to the subtlety of the t( IO; 1 1) translocation.
I Op 1 I 27.12. 33 The leukemia of patient B was previously reported as having a t(9; I l)(q33;q23) translocation. Using a YAC clone spanning the HRX breakpoint, it was shownI5 that the distal portion of HRX was transferred to chromosome 9. Banded analysis also showed additional material on chromosome I2p 13 and a loss from I Op 1 I . From the information presented here. we can reinterpret this karyotype as having a complex translocation that results in the fusion of the distal part of IOp onto chromosome 11 at band q23. The lack of a reciprocal AFIO/HRX product in the RNA from patient B is consistent with the transfer of I lq23-I lqter onto chromosome 9. The similar lack of AFIO/HRX product in patient A suggests that this may be a consistent feature of this translocation. Because it has been previously shown" that the distal portion of the HRX YAC is transferred to chromosome I O in the leukemia from patient A, this lack may be due to a small deletion around the junction between the two chromosomes.
In view of the clear signals located on chromosome 19 with our AFlO cosmid probe. it is interesting to note that heterogeneity has been observed at the karyotypic level for the t( 1 I ; 19)."' Furthermore. a leukemia has been observed with the t( I I ; 19) translocation involving the HRX gene but with no apparent involvement of the ENL gene:" Although these data suggest that a second target gene lies on 19p and that it could be related to AFIO, a novel partner gene, ELL. has recently been reported" on 19p and is unrelated to AFIO.
Although the cytogenetic evidence suggests that the critical product is expressed from the der( I 1 ) chromosome. a role for the reciprocal proteins in the malignant transformation cannot yet be excluded. The apparent lack of a reciprocal AFIO/HRX protein suggests that the t(10; I l ) may differ from other 1 lq23 translocations as reciprocal products have been found from the t(4; I l),' the t( I I ; 19); the t(9; 1 I),' and the t( I ; 1 l)." More leukemias will have to be examined to determine if the lack of an AFIO/HRX protein, expected to contain of two fused zinc finger domains, is a consistent feature of the t( IO; 11) translocation.
